Zirus has exclusive rights to hundreds of human host gene targets that provide an extensive platform for blocking viral infection. Zirus scientists are currently using the cost effective and efficient gene trap to discover on average one additional gene target each day. These numbers greatly increase the potential for success in creating new blockbuster antiviral drugs.

Zirus also has discovered potential drugs that can block each of its hundreds of targets in vitro. Inhibiting these targets blocks infection of all commercially important viruses tested to date in vitro. Since the company's gene targets include targets that can be used to block influenza virus, the targets provide a platform to develop drugs to block pandemic flu. The targets also provide an extensive platform for the development of broad spectrum antivirals (Zirus Antivirotics™) for the treatment and prevention of virtually any virus created by nature or by a terrorist.

The extensive platform of host proteins targets provides Zirus the opportunity to discover drugs already approved for other clinical indications that also work to prevent viral infection through one of the companies targets. Such "repurposed drugs" would be available to treat viral infection in a shorter time frame with less cost.

Zirus has many opportunities for success with its broad platform of targets.